Riboflavin 5'-phosphate ophthalmic
Brand names: Photrexa Cross-Linking Kit · Active ingredient: Riboflavin 5'-Phosphate Sodium Anhydrous
In short: PHOTREXA® VISCOUS and PHOTREXA® are indicated for use in corneal collagen cross-linking in combination with the KXL® System for the treatment of
What is Riboflavin 5'-phosphate ophthalmic used for?
PHOTREXA® VISCOUS and PHOTREXA® are indicated for use in corneal collagen cross-linking in combination with the KXL® System for the treatment of
Riboflavin 5'-phosphate ophthalmic dosage
Using topical anesthesia, debride the epithelium to a diameter of approximately 9 mm using standard aseptic technique. Post epithelial debridement, instill 1 drop of PHOTREXA VISCOUS topically on the eye every 2 minutes for 30 minutes.
At the end of the 30 minute soaking period, examine the eye under the slit lamp for the presence of a yellow flare in the anterior chamber. If the yellow flare is not detected, instill 1 drop of PHOTREXA VISCOUS every 2 minutes for an additional 2 to 3 drops and recheck for the presence of a yellow flare. This process can be repeated as necessary.
Once the yellow flare is observed, perform ultrasound pachymetry. If corneal thickness is less than 400 microns, instill 2 drops of PHOTREXA every 5 to 10 seconds until the corneal thickness increases to at least 400 microns. Irradiation should not be performed unless this 400 micron threshold is met and the yellow flare is seen.
Irradiate the eye for 30 continuous minutes at 3mW/cm2 at a wavelength of 365 nm, centered over the cornea, using the KXL System as per the instructions in the KXL manual. During irradiation, continue topical instillation of PHOTREXA VISCOUS onto the eye every 2 minutes for the 30 minute irradiation period.
For topical ophthalmic use. Do not inject.
Single use PHOTREXA VISCOUS and PHOTREXA only. Discard syringe(s) after use.
PHOTREXA VISCOUS and PHOTREXA are for use with the KXL System only.
PLEASE REFER TO THE KXL OPERATOR'S MANUAL FOR SPECIFIC DEVICE INSTRUCTIONS.
How to take Riboflavin 5'-phosphate ophthalmic — instructions & advice from the label
Patients should be advised not to rub their eyes for the first five days after their procedure.
Patients may be sensitive to light and have a foreign body sensation. Patients should be advised that there may be discomfort in the treated eye and that sunglasses may help with light sensitivity.
If patients experience severe pain in the eye or any sudden decrease in their vision, they should be advised to contact their physician immediately.
If the bandage contact lens that was placed on the patient's eye on the day of treatment falls out or becomes dislodged, the patient should be advised not to replace it and to contact their physician immediately.
PHOTREXA® VISCOUS (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146%, PHOTREXA® (riboflavin 5'-phosphate ophthalmic solution) 0.146% and the KXL® System are marketed by: Avedro, a Glaukos company, 30 North Avenue, Burlington, MA 01803.
Version: Issued February 2025
ML-00043 REV4
Warnings & precautions
Do not take this medicine if: None.
Ulcerative keratitis can occur. Monitor for resolution of epithelial defects. .
Riboflavin 5'-phosphate ophthalmic side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Ulcerative keratitis [Warnings and Precautions (Section 5)]
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of the corneal collagen cross-linking procedure was evaluated in 3 randomized, parallel-group, open-label, sham-controlled trials; patients were followed up for 12 months. Study 1 enrolled patients with progressive keratoconus or corneal ectasia following refractive surgery. Study 2 enrolled only patients with progressive keratoconus, and Study 3 enrolled only patients with corneal ectasia following refractive surgery. In each study, only one eye of each patient was designated as the study eye. Study eyes were randomized to receive one of the two study treatments (CXL or sham) at the baseline visit and were followed up at Day 1, Week 1, and Months 1, 3, 6, and 12. At Month 3 or later, sham study eyes and non-study eyes had the option of receiving CXL treatment, and were followed-up for 12 months from the time of receiving CXL treatment. Each CXL treated eye received a single course of CXL treatment only. …
About this medicine
PHOTREXA VISCOUS (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% and PHOTREXA (riboflavin 5'-phosphate ophthalmic solution) 0.146% are intended for topical ophthalmic administration as part of corneal collagen cross-linking with the KXL System.
PHOTREXA VISCOUS and PHOTREXA are supplied as:
PHOTREXA VISCOUS in a 3 mL glass syringe containing sterile 1.56 mg/mL riboflavin 5'-phosphate in 20% dextran ophthalmic solution for topical administration.
PHOTREXA in a 3 mL glass syringe containing sterile 1.46 mg/mL riboflavin 5'-phosphate ophthalmic solution for topical administration.
PHOTREXA VISCOUS (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% is a yellow sterile buffered viscous solution containing 1.56 mg/mL riboflavin 5'-phosphate and 20% dextran. The pH of the solution is approximately 7.1 and the osmolality is 284-368 mOsm/kg. Each 1 mL of solution contains 1.64 mg of riboflavin 5'-phosphate sodium (equivalent to 1.284 mg riboflavin). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f82cfe92-1a24-11e3-8ffd-0800200c9a66. Read the full official label on DailyMed.
Related medicines
Azithromycin Latanoprost Amoxicillin and Clavulanate Cephalexin Sulfamethoxazole and Trimethoprim Ofloxacin Timolol Cefdinir